EPICC Accomplishments

45 clinical trials opened.

Over 1,300 children enrolled on clinical trials.

Over 420 papers published in high-impact peer-reviewed journals.

• As the years progressed with the PCDT and EPICC, the number of papers published by multi-institutions increased significantly. In recent years, the vast majority of publications are collaborations between institutions involved with EPICC.

56 patent applications.

Received over $167 million USD in leveraged funding that occurred as a direct result of the work accomplished as part of the PCDT/EPICC. The foundational work of the group led to this further funding for other scientific discovery into hard-to-cure childhood cancers.

AACR Team Science award winner for 2021.

Played a pivotal role in the FDA approval of CD19 and CD22 CAR T-cell therapy. Learned important lessons on mechanisms of anti-tumor activity, immune escape and patient management.

Have shown activity of HER2-directed CAR T-cells in pediatric sarcoma and pediatric glioblastoma, demonstrated durable complete remissions in osteosarcoma and rhabdomyosarcoma, and have initiated novel trials for a variety of pediatric solid tumors with several others in development. (AACR article)

Utilized a proteogenomic approach to develop and deliver therapies for novel pediatric immunotherapeutic targets.

• Encouraging preclinical data now translating towards clinical testing, with signs of clinical efficacy for some of the most lethal childhood cancers

  • CAR T-cell (and pcCAR T-cell)

  • mAbs, bi-specific mAbs, ADCs, mAb-cytokine fusion proteins, combination immunotherapies